Expression of reversion-inducing cysteine-rich protein with Kazal motifs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus: Links to disease activity, damage accrual and matrix metolloproteinase 9 secretion

Journal of International Medical Research

Volumn 36, Issue 4, 2008, Pages 704-713

  Hou, C ^a   Zhang, Y ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Gene expression; Matrix metalloproteinases; Peripheral blood mononuclear cells; Reversion inducing cysteine rich protein with Kazal motifs; Systemic lupus erythematosus

Indexed keywords

GELATINASE B; MESSENGER RNA; REVERSION INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIFS; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; RECK PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN TARGETING; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CYTOLOGY; GENETICS; HOSPITALIZATION; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PATHOPHYSIOLOGY; QUESTIONNAIRE; SECRETION;

ADULT; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 52049097050     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600412     Document Type: Article

References (27)

1. Belmont HM, Abramson SB, Lie JT: Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 9-22.
2. Takeuchi T, Aoki K, Koide J, et al: Systemic lupus erythematosus with necrotizing vasculitis and upregulated expression of VLA-4 antigen. Clin Rheumatol 1995; 14: 370-374.
3. Lim KL, Lowe J, Powell RJ: Skeletal muscle lymphocytic vasculitis in systemic lupus erythematosus: relation to disease activity. Lupus 1995; 4: 148-151.
4. Faber-Elmann A, Sthoeger Z, Tcherniack A, et al: Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127: 393-398.
5. Opdenakker G, Van den Steen PE, Dubois B, et al: Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859.
6. Oh J, Takahashi R, Kondo S, et al: The membrane-anchored MMP inhibitor RECK is a key regulator of axtracellular matrix integrity and angiogenesis. Cell 2001; 107: 789-800.
7. Noda M, Oh J, Takahashi R, et al: RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003; 22: 167-175.
8. Van der Jagt MF, Sweep FC, Waas ET, et al: Correlation of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. Cancer Lett 2006; 237: 289-297.
9. Masui T, Doi R, Koshiba T, et al: RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res 2003; 9: 1779-1784.
10. Takemoto N, Tada M, Hida Y, et al: Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer 2007; 58: 376-383.
11. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
12. Bombardier C, Gladman DD, Urowitz MB, et al: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
13. Gladman D, Ginzler E, Goldsmith C, et al: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363-369.
14. Hill HD, Straka JG: Protein determination using bicinchoninic acid in the presence of sulfhydryl reagents. Anal Biochem 1988; 170: 203-208.
15. Liu Y, Zheng M, Yin WH, et al: Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33: 340-343, 348.
16. Robak E, Wierzbowska A, Chmiela M, et al: Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythematosus. Mediators Inflamm 2006; 2006: 17898.
17. Makowski GS, Ramsby ML: Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus. Mol Pathol 2003; 56: 244-247.
18. Matache C, Stefanescu M, Dragomir C, et al: Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 2003; 20: 323-331.
19. Mawrin C, Brunn A, Rocken C, et al: Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) 2003; 105: 365-372.
20. Van den Steen PE, Dubois B, Nelissen I, et al: Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
21. Leppert D, Waubant E, Galardy R, et al: T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995; 154: 4379-4389.
22. Zucker S, Cao J, Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-6650.
23. Yi EY, Park SY, Song HS, et al: KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. Exp Mol Med 2006; 38: 502-508.
24. Thabet MM, Huizinga TW: Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 2006; 7: 1014-1019.
25. Rabien A, Burkhardt M, Jung M, et al: Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. Eur Urol 2007; 51: 1259-1266.
26. Cho CY, Wang JH, Chang HC, et al: Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. J Cell Physiol 2007; 213: 65-69.
27. Van Lent PL, Span PN, Sloetjes AW, et al: Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 368-374.